Magnetic resonance imaging contrast agents: Overview and perspectives |
| |
| Affiliation: | 1. Department of Biomedical Engineering, UNIST (Ulsan National Institute of Science & Technology), Ulsan, South Korea;2. Korea Basic Science Institute, Ochang, South Korea;3. Department of Global Biomedical Engineering, IBS Center for Neuroscience Imaging Research, Sungkyunkwan University, Suwon, South Korea;4. Martinos Center for Biomedical Imaging, Charlestown, MA, USA;5. Department of Radiology, Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;1. Department of Medical Nanobiotechnology, Pirogov Russian National Research Medical University, Moscow, Russia;2. Division of Fundamental and Applied Neurobiology, Serbsky State Research Center of Social and Forensic Psychiatry, Moscow, Russia;3. Laboratory of Chemical Design of Bionanomaterials, Chemistry Department, M.V. Lomonosov Moscow State University, Moscow, Russia;4. Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA;5. Center for Nanotechnology in Drug Delivery and Division of Molecular Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;6. Electron Microscopy for Materials Science (EMAT), University of Antwerp, Groenenborgerlaan 171, Belgium |
| |
| Abstract: | Magnetic resonance imaging (MRI) is a non-invasive clinical imaging modality, which has become widely used in the diagnosis and/or staging of human diseases around the world. Some MRI examinations include the use of contrast agents. The categorizations of currently available contrast agents have been described according to their effect on the image, magnetic behavior and biodistribution in the body, respectively. In this field, superparamagnetic iron oxide particles and soluble paramagnetic metal chelates are two main classes of contrast agents for MRI. This review outlines the research and development of MRI contrast agents. In future, the ideal MRI contrast agent will be focused on the neutral tissue- or organ-targeting materials with high relaxivity and specificity, low toxicity and side effects, suitable long intravascular duration and excretion time, high contrast enhancement with low dose in vivo, and with minimal cost. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
